A Phase 3 interventional study of PA21 (2.5 g tablet containing 500 mg iron) and Sevelamer carbonate in Chronic Kidney Disease Requiring Chronic Dialysis, sponsored by Vifor Pharma. Completed at 15 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-01.
Sponsored by Vifor Pharma (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 3, randomised, active controlled, multicentre extension study to investigate the long-term safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients. This is an extension study to PA-CL-05A (NCT01324128), subjects have already been enrolled and have been treated with study medication for at least 24 weeks.
Vifor Pharma is the lead sponsor of 22 studies on the registry; none are open to participants now.
First submitted before Vifor Pharma became part of CSL Limited.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PA21 (2.5 g tablet containing 500 mg iron)
Drug: Sevelamer carbonate
Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
Film coated, compressed tablets. Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day).
Change From Baseline and Levels at Each Time Point for Serum Phosphorus
Endpoint is Week 28 or the latest available measurement after baseline when Week 28 data is missing.
Time frame: Every 4 weeks from baseline to Week 28
Change From Baseline and Levels at Each Time Point for Serum Calcium
Endpoint is Week 28 or the latest available measurement after baseline when Week 28 data is missing.
Time frame: Every 4 weeks from baseline to Week 28
Change From Baseline and Levels at Each Time Point for Serum Intact Parathyroid Hormone (iPTH)
Endpoint is Week 28 or the latest available measurement after baseline when Week 28 data is missing.
Time frame: Every 4 weeks from baseline to Week 28
| Milestone | PA21 | Sevelamer Carbonate |
|---|---|---|
| Started | 391 | 268 |
| Completed | 322 | 227 |
| Not completed | 69 | 41 |
Endpoint is Week 28 or the latest available measurement after baseline when Week 28 data is missing.
| mg/dL | PA21 | Sevelamer Carbonate |
|---|---|---|
| Change from Baseline to Week 4 (n = 346, 236) | -0.2 ± 1.33 | -0.1 ± 1.47 |
| Change from Baseline to Week 8 (n = 325, 238) | -0.2 ± 1.38 | 0.1 ± 1.56 |
| Change from Baseline to Week 12 (n = 322, 242) | -0.0 ± 1.43 | 0.2 ± 1.55 |
| Change from Baseline to Week 16 (n = 313, 228) | 0.0 ± 1.57 | 0.2 ± 1.75 |
| Change from Baseline to Week 20 (n = 300, 221) | -0.0 ± 1.46 | 0.1 ± 1.44 |
| Change from Baseline to Week 24 (n = 286, 208) | 0.1 ± 1.53 | 0.2 ± 1.78 |
| Chnage from Baseline to Week 28 (n = 287, 210) | 0.2 ± 1.52 | 0.2 ± 1.76 |
| Change from Baseline to Endpoint (n = 384, 260) | 0.1 ± 1.62 | 0.3 ± 1.79 |
Endpoint is Week 28 or the latest available measurement after baseline when Week 28 data is missing.
| mg/dL | PA21 | Sevelamer Carbonate |
|---|---|---|
| Change from Baseline to Week 4 (n = 346, 236 | -1.2 ± 12.07 | -0.8 ± 13.37 |
| Change from Baseline to Week 8 (n = 325, 238) | -1.2 ± 12.30 | 1.5 ± 14.40 |
| Change from Baseline to Week 12 (n = 321, 242) | 0.1 ± 12.94 | 1.9 ± 13.79 |
| Change from Baseline to Week 16 (n = 313, 228) | 0.5 ± 14.04 | 2.0 ± 16.05 |
| Change from Baseline to Week 20 (n = 300, 221) | 0.4 ± 13.24 | 1.6 ± 13.29 |
| Change from Baseline to Week 24 (n = 284, 207) | 1.1 ± 13.57 | 2.2 ± 15.74 |
| Change from Baseline to Week 28 (n = 286, 210) | 2.3 ± 13.52 | 2.3 ± 16.39 |
| Change from Baseline to Endpoint (n = 365, 258) | 1.5 ± 13.86 | 2.9 ± 16.68 |
Endpoint is Week 28 or the latest available measurement after baseline when Week 28 data is missing.
| pg/mL | PA21 | Sevelamer Carbonate |
|---|---|---|
| Change from Baseline to Week 4 (n = 365, 252) | 11.8 ± 177.39 | 25.9 ± 186.42 |
| Change from Baseline to Week 8 (n = 362, 258) | 8.6 ± 204.39 | 40.8 ± 201.18 |
| Change from Baseline to Week 12 (n = 352, 252) | 28.9 ± 315.81 | 64.1 ± 204.11 |
| Change from Baseline to Week 16 (n = 341, 241) | 54.5 ± 352.92 | 52.3 ± 210.35 |
| Change from Baseline to Week 20 (n = 334, 236) | 28.0 ± 233.13 | 72.1 ± 228.03 |
| Change from Baseline to Week 24 (n = 320, 226) | 27.7 ± 271.31 | 79.6 ± 253.65 |
| Change from Baseline to Week 28 (n = 310, 222) | 53.0 ± 287.19 | 71.5 ± 278.03 |
| Change from Baseline to Endpoint (n = 381, 260) | 52.3 ± 273.14 | 67.5 ± 270.06 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PA21 | — | 78/391 (19.9%) | 208/391 (53.2%) |
| Sevelamer Carbonate | — | 52/267 (19.5%) | 169/267 (63.3%) |
| Event | PA21 | Sevelamer Carbonate |
|---|---|---|
| Fluid overloadMetabolism and nutrition disorders | 4/391 | 6/267 |
| PneumoniaInfections and infestations | 6/391 | 6/267 |
| AnaemiaBlood and lymphatic system disorders | 1/391 | 3/267 |
| Atrial fibrillationCardiac disorders | 1/391 | 3/267 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 2/391 | 3/267 |
| HaematomaVascular disorders | 4/391 | 0/267 |
| Cardiac failure congestiveCardiac disorders | 3/391 | 1/267 |
| Cerebrovascular accidentNervous system disorders | 3/391 | 0/267 |
| Chest painGeneral disorders | 3/391 | 1/267 |
| CholelithiasisHepatobiliary disorders | 3/391 | 0/267 |
| Event | PA21 | Sevelamer Carbonate |
|---|---|---|
| HyperphosphataemiaMetabolism and nutrition disorders | 47/391 | 29/267 |
| HypertensionVascular disorders | 38/391 | 20/267 |
| Hyperparathyroidism secondaryEndocrine disorders | 15/391 | 23/267 |
| DiarrhoeaGastrointestinal disorders | 32/391 | 15/267 |
| HypotensionVascular disorders | 19/391 | 21/267 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 26/391 | 16/267 |
| HyperkalaemiaMetabolism and nutrition disorders | 17/391 | 16/267 |
| NauseaGastrointestinal disorders | 23/391 | 11/267 |
| HypophosphataemiaMetabolism and nutrition disorders | 22/391 | 14/267 |
| AnaemiaBlood and lymphatic system disorders | 15/391 | 15/267 |
For baseline characteristics, data from All Randomised patients was used.
| Age, Continuous(years) | PA21 | Sevelamer Carbonate | Total |
|---|---|---|---|
| Mean | 55.2 ± 13.20 | 55.6 ± 14.58 | 55.4 ± 13.77 |
| Age, Categorical(Participants) | PA21 | Sevelamer Carbonate | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 296 | 190 | 486 |
| >=65 years | 95 | 78 | 173 |
| Sex: Female, Male(Participants) | PA21 | Sevelamer Carbonate | Total |
|---|---|---|---|
| Female | 171 | 102 | 273 |
| Male | 220 | 166 | 386 |
| Region of Enrollment(participants) | PA21 | Sevelamer Carbonate | Total |
|---|---|---|---|
| United States | 154 | 133 | 287 |
| Europe | 85 | 49 | 134 |
| Croatia | 16 | 8 | 24 |
| Russian Federation | 65 | 44 | 109 |
| Serbia | 37 | 18 | 55 |
| Ukraine | 32 | 15 | 47 |
| South Africa | 2 | 1 | 3 |
The record gives a start of Sep 2011, a primary completion of Oct 2012 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 1 year 4 months after primary completion. A results delay was requested in Aug 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PA21